Monte Rosa Therapeutics, Inc. - 8-K Filing

Monte Rosa Therapeutics receives $50M milestone payment from Novartis for initiation of Phase 2 study in Sjögren's disease (Items: 7.01 Regulation FD DisclosureOn September 8, 2026, Monte Rosa Therapeutics, Inc, 8.01 Other EventsAs previously disclosed, the Company is party to a global exclusive development and commercialization license agreement (the “Nov, 9.01 Financial Statements and Exhibits(d) Exhibits 99)

SEC EDGAR · September 8, 2026, 11:44 UTC

Tickers: $GLUE

Read the full article at SEC EDGAR

More Regulatory news

OLD NATIONAL BANCORP /IN/ - 8-K Filing SEC EDGAR · November 12, 2026, 15:20 UTC
AMTECH SYSTEMS INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:16 UTC
REGIONAL HEALTH PROPERTIES, INC - 8-K Filing SEC EDGAR · November 12, 2026, 15:09 UTC
Bitwise Avalanche ETF - 8-K Filing SEC EDGAR · November 12, 2026, 15:06 UTC
MiNK Therapeutics, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:05 UTC
Future Vision II Acquisition Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
THUNDER MOUNTAIN GOLD INC - 10-Q Filing SEC EDGAR · November 12, 2026, 15:00 UTC
MiNK Therapeutics, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:49 UTC
SusGlobal Energy Corp. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:42 UTC
Ideal Power Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:25 UTC